<h2>Beschikbare Curious Cases</h2>
<h3>Echte patiëntverhalen – uw keuzes maken het verschil</h3>

<p>Een pati&euml;nt met een voorgeschiedenis van psoriasis en myelodysplasie presenteert zich met aanhoudende anemie, leukopenie en nieuwe respiratoire klachten. Er zijn aanwijzingen voor een onderliggende systemische oorzaak, maar het plaatje blijft diffuus. U krijgt toegang tot labuitslagen, beeldvorming en aanvullende onderzoeken. Krijgt u de puzzel compleet en komt u tot de juiste diagnose?</p>


<p>Een verder gezonde man van 40 jaar komt met een vergrote milt zonder duidelijke verklaring. Bloedonderzoek laat milde trombocytopenie zien, maar levert geen sluitend antwoord op. Tijdens het diagnostisch traject ontdekt u afwijkingen die u in een andere richting sturen. Herkent u het patroon en vraagt u de juiste test aan?</p>


<p>Een jonge pati&euml;nt met langdurige vermoeidheid en gewrichtsklachten is gediagnosticeerd met seronegatieve reumato&iuml;de artritis. Ondanks behandeling blijven de klachten bestaan en komen er nieuwe symptomen bij. U onderzoekt stap voor stap waar het misgaat en welke hematologische afwijkingen over het hoofd zijn gezien. Weet u de juiste diagnose alsnog te stellen?</p>


<h2>Begin de diagnose</h2>
<h3>Aan u de beurt: wat zou ú doen?</h3>

<h2>Hematologen over Curious Cases</h2>
<h3>Ervaringen van uw collega's</h3>

<p>Curious Cases laat u meedenken met complexe patiëntverhalen gebaseerd op echte casussen uit de praktijk. U bepaalt zelf welke stappen u neemt in het diagnostisch proces en krijgt meteen feedback. Praktisch, to-the-point en ontworpen voor specialisten die hun klinisch inzicht willen aanscherpen.</p>

<p>De situaties zijn herkenbaar voor elke hematoloog en komen voort uit de dagelijkse praktijk.</p>


<p>Elke casus duurt ongeveer 10 tot 15 minuten &ndash; ideaal om even tussendoor te doen.</p>


<p>De focus ligt op praktische keuzes: wat doet u wel en wat niet &ndash; en waarom?</p>


<p>Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.</p>


Wij staan klaar

Klinische patiëntcasussen die u aan het denken zetten – waar de diagnose niet voor zichzelf spreekt. Sommige klachten passen niet meteen in een standaardplaatje. Herkent u de signalen die wijzen op een minder voor de hand liggende oorzaak?

GAUCHER

RARE-DISEASE

Curious Cases - Daag uzelf uit met complexe hematologische casussen

<p><strong>PREVIOUS EPISODE</strong></p>
<h2><strong>Polyp Gossip Episode 3: Living with CRSwNP: Daily Challenges and Solutions</strong></h2>

<p>In this episode of Polyp Gossip, we dive into the real-life experiences of patients living with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), exploring how the condition impacts their daily routines, relationships, and overall well-being. Our guests share their journeys, shedding light on the emotional and physical toll of the condition.</p>

<p>Surgical Whispers: is One Surgery Enough Before Biologics?</p>


<p>Scent-sational Secrets: The Smell Loss Truth</p>


<h2>Biography</h2>
<h3>Wytske Fokkens</h3>
<p>Wytske J. Fokkens, MD, PhD, is a Professor at the Department of Otorhinolaryngology at the Academic Medical Center in Amsterdam. She is the Director of the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) Innovation Forum, Chairperson of the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), and a member of the European Rhinologic Society Foundation Committee.&nbsp;</p>
<p>Prof. Fokkens is a founding member of EUFOREA, member of the Allergic Rhinitis and its Impact on Asthma Initiative, which develops guidelines for the management of concurrent allergic rhinitis and asthma, and center leader for the Global Allergy and Asthma European Network, a consortium of leading European research centers specializing in allergic diseases. She received the 2015 Paul Ehrlich Award for Experimental Research from the European Academy of Allergy and Clinical Immunology (EAACI) in 2015 and is an honorary member of EAACI, the Spanish and Greek Societies of Otorhinolaryngology, and the Romanian Rhinologic Society.&nbsp;</p>
<p>Prof. Fokkens is the author of more than 500 peer-reviewed papers on allergy and rhinology. Her main field of interest is sinus surgery and mucosal pathology of the upper and lower airways. She has written a textbook on rhinology and skull base surgery and has led an advanced sinus surgery course for more than 15 years. She serves as Editor-in-Chief of&nbsp;<em>Rhinology</em>&nbsp;and Associate Editor of&nbsp;<em>Allergy</em>.</p>
<h3>Peter Hellings</h3>
<p>Peter W. Hellings, MD, PhD, is a Professor and Clinic Head at the Department of Otorhinolaryngology at the University Hospitals of Leuven, and a Guest Professor at Ghent University, Belgium.</p>
<p>Prof. Hellings' research has led to novel insights into the pathophysiology of allergy and chronic airway inflammation, with over 350 scientific publications in top journals in the field of allergology, rhinology, and respiratory care. He is the founder of the European Forum for Research and Education in Allergy and Airway Diseases, an international nonprofit involving a consortium of European key opinion leaders aiming at the implementation of optimal care for chronic respiratory diseases. He is also the founder and director of the European Rhinoplasty Course and a member of European and American guideline committees.</p>

In this episode of Polyp Gossip, we dive into the real-life experiences of patients living with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), exploring how the condition impacts their daily routines, relationships, and overall well-being. Our guests share their journeys, shedding light on the emotional and physical toll of the condition.

Polyp Gossip – Episode 3

CHRONIC-RHINOSINUSITIS-WITH-NASAL-POLYPS-CRSWNP

RESPIRATORY

<h2>Missed the live session? No worries!</h2>

<p>Join Dr. Andreas Kindmark as he discusses the assessment of bone health and the management of bone disease in patients with Lysosomal Storage Diseases (LSDs).</p>

<h3>This session covers:</h3>
<ul>
 <li>The critical role of <strong>early identification</strong> and <strong>accurate measurement</strong> of bone disease</li>
 <li>Techniques and methodologies for <strong>assessing bone health</strong></li>
 <li>Insights into how <strong>bone involvement manifests</strong> in various lysosomal storage disorders</li>
</ul>

<p>Dr. Andreas Kindmark is an MD, Associate Professor, and Senior Consultant at <strong>Uppsala University Hospital, Sweden</strong>. He is a Certified Clinical Densitometrist, and coordinating Process Leader for the Uppsala University Hospital national highly specialized care (NHV) units for skeletal dysplasias and osteogenesis imperfecta. He is also a member of the Management and Monitoring working group for the International Working Group for Gaucher disease. Specialized in metabolic diseases, bone, and mineral metabolism, he brings invaluable expertise to this discussion.</p>

<h2>Who should watch?</h2>
<p>This webinar is interesting for:</p>
<ul>
 <li>Endocrinologists</li>
 <li>Hematologists</li>
 <li>Radiologists</li>
</ul>

<h2>Part I: Bone Health Fundamentals &amp; Diagnostic technologies</h2>
<p>Gain a deeper understanding of how&nbsp;<strong>bone mass changes throughout life</strong>&nbsp;and why it matters to patients with LSDs. In this video, explore&nbsp;<strong>advanced techniques</strong>&nbsp;for assessing bone health, and learn the critical roles of different bone cells in maintaining skeletal integrity.</p>

Addressing Bone Disease in Lysosomal storage diseases

<h2>Part II: The impact of LSDs on Bone Health</h2>
<p>How can&nbsp;<strong>early intervention</strong>&nbsp;prevent irreversible bone damage in patients with&nbsp;<strong>LSDs</strong>? Explore how&nbsp;<strong>LSDs</strong>, especially&nbsp;<strong>Gaucher disease</strong>, impact skeletal health. Learn how&nbsp;<strong>advanced imaging</strong>&nbsp;techniques can enhance diagnosis and guide better treatment strategies, ultimately improving the quality of life for patients.</p>

<p>Mucus plugs are a critical yet often overlooked aspect of asthma that significantly contribute to airway obstruction and disease progression.<sup>1</sup></p>
<p>Understanding the mechanisms behind their formation, particularly the role of type 2 inflammation and the cytokine IL-13, is essential for improving asthma management.<sup>1</sup></p>

In healthy lungs, mucus is vital<sup>1</sup>

<h2>Type 2 inflammation and IL-13</h2>
<p>Type 2 inflammation is characterized by the activation of T-helper 2 (Th2) cells and innate lymphoid cells (ILC2s), leading to the production of cytokines, particularly IL-4, IL-5, and IL-13.<sup>1</sup></p>
<p>IL-13 is a key driver of mucus hypersecretion in asthma, significantly increasing the expression of MUC5AC, a mucin that contributes to mucus plug formation.<sup>1</sup></p>

<h2>IL-13 is mainly responsible for mucus overproduction and decreased mucociliary clearance<sup>1,2</sup></h2>

<p><strong>Increased levels of MUC5AC lead to mucus plugs that are resistant to clearance, contributing to airway obstruction and exacerbations.<sup>1</sup></strong></p>

<p>In asthma, the ratio of MUC5AC to MUC5B is dysregulated, with MUC5AC being dramatically upregulated, particularly in eosinophilic asthma. This change results in mucus that is stickier and more tenacious.<sup>1</sup></p>

<h4>MUCUS PLUGGING IS A KEY COMPONENT OF REMODELING IN ASTHMA, LEADING TO FIXED OBSTRUCTION AND LUNG FUNCTION DECLINE<sup>3-5</sup></h4>

<h2>Presence of mucus plugs is associated with worsening clinical asthma outcomes<sup>6</sup></h2>

<p data-font="small">Plugs contribute to ongoing inflammation, creating a cycle that exacerbates symptoms and leads to airway remodeling.</p>

<p>Patients with high mucus scores have substantially<sup>2,6</sup>:</p>
<ul>
 <li><strong>increased IL-13 levels and eosinophil counts</strong> in sputum</li>
 <li><strong>increased level of FeNO</strong>, another biomarker of type 2 inflammation</li>
</ul>

Mucus plugs can be identified and quantified using HRCT imaging of the lungs<sup>4</sup>

The burden of mucus plugs persists in severe asthma patients and impacts OoL<sup>5</sup>

ASTHMA

<h2>To know more about mucus plugging</h2>

<p>In deze webinar bespreekt professor Bart Lambrecht mucusplugs en hun cruciale rol bij longaandoeningen.</p>


<p>Republished with permission of American Society for Clinical Investigation, from Journal of Clinical Investigation, Dunican EM, Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction, Vol 128/No. 3, Copyright 2018; permission conveyed through Copyright Clearance Center, Inc. Reprinted from the American Journal of Respiratory and Critical Care Medicine, Tang M, et al, Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time, Vol 205/Issue 9,Copyright 2022, with permission from the American Thoracic Society.</p>
<p>*Data from 146 of the 658 adult patients with asthma enrolled in SARP. Of those included in SARP (n=658), 66% of patients met American Thoracic Society/European Respiratory Society criteria for severe asthma. Patients were non-smokers and were required to have evidence of bronchial hyperresponsiveness or reversible airflow obstruction.</p>
<p><strong>ACT</strong>, Asthma Control Test; <strong>FeNO</strong>, fractional exhaled nitric oxide; <strong>FEV1</strong>, forced expiratory volume in 1 second; <strong>OCS</strong>, oral corticosteroid; <strong>SARP</strong>, Severe Asthma Research Program</p>

Mucus plugs in Asthma, and the influence of Type 2 inflammation

<p>EASD and ADA recommend the addition of basal insulin for people with T2DM who do not achieve glycemic goals on a GLP-1 RA-based regimen.<sup>*2,3</sup><br>
  The management of type 2 diabetes (T2D) often requires treatment intensification to achieve optimal glycemic control. The DELIVER-G study explores the real-world outcomes of adding Insulin Glargine 300 U/mL (Gla-300) to GLP-1 receptor agonist (GLP-1RA) therapy in people with type 2 diabetes (PWD2). This study builds on findings from the RESTORE-G real-world study, which examined treatment intensification following GLP-1RA therapy.</p>

Adding Toujeo<sup>®</sup> to GLP-1 RA significantly improved glycemic control<sup>1</sup>

Adding Toujeo<sup>®</sup> to GLP-1 RA did not significantly increase hypoglycemia<sup>1</sup>

Adding Toujeo<sup>®</sup> to GLP-1 RA did not increase weight and body mass index (BMI)<sup>1</sup>

<h2>Study design</h2>
<p>DELIVER-G was a retrospective analysis of 271 patients with type 2 diabetes receiving GLP-1 RA therapy who were insulin-naïve prior to subsequent treatment intensification with Toujeo<sup>®</sup>. DELIVER-G analysed data from a large US electronic medical record data source (IBM<sup>®</sup> Explorys).</p>

<h2>Study population</h2>
<p>Insulin-naïve adult patients (N=271) with T2DM receiving GLP-1 RA therapy ± OAD(s) that was subsequently intensified by adding Toujeo<sup>®</sup>. A total of 156 (57,6%) patients received daily GLP-1 RA and 115 (42,2%) received weekly GLP-1 RA before treatment intensification; 250 (92,3%) patients were receiving at least one OAD prior to intensification with Toujeo<sup>®</sup> (the mean number of OADs was two).</p>
<p><sup>*</sup>Data were extracted from a US electronic medical record data source (IBM<sup>®</sup> Explorys). Patients selected for inclusion had ≥12 months’ pre-Toujeo<sup>®</sup> data and ≥6 months of follow-up data.</p>
<p><sup>**</sup>Paired Student’s t-test. Change in HbA1c between baseline and follow-up was assessed using the last value recorded within the 3- to 9-month period following intensification with Toujeo<sup>®</sup>.</p>
<p><sup>†</sup>Identified by ICD-9 or ICD-10 codes, or a blood glucose recording ≤70 mmol/L, or the number of hypoglycaemic events in the 6-month baseline period vs the 6-month follow-up period. Incidence of any hypoglycaemia pre- and post-intensification with Toujeo<sup>®</sup> was 8,49% and 9,59%, respectively (p=0,513). Paired Student’s t-test.</p>
<p><sup>‡</sup>One hypoglycaemia-associated inpatient visit was recorded during the baseline period and none during the follow-up period after intensification with Toujeo<sup>®</sup>; no hypoglycaemia-associated ED visits were recorded during the baseline period and one during the follow-up period. Incidence of any (8,49% vs 9,59%, p=0,513), and inpatient/ED-associated hypoglycaemia (0,37% vs 0,74%, p=1,000), as well as event rates of any (0,33 vs 0,46 PPPY, p=0,170) and inpatient/ED-associated hypoglycaemia (0,01 vs 0,04 PPPY, p=0,466) were similar before and after addition of Toujeo<sup>®</sup>. When analysed by baseline GLP-1 RA regimen, incidence of hypoglycaemia increased from baseline to follow-up (3,9% to 8,3%, p=0,02; event rate 0,21 to 0,44 PPPY, p=0,017) for those on daily GLP-1RAs. No significant change was observed for those on weekly GLP-1 RAs.</p>

TYPE-2-DIABETES

DIABETES

<p data-font="small">CLICK HERE TO READ THE FULL PUBLICATION</p>

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†<sup>1</sup>

The Deliver-G study

<p>Atopic dermatitis (AD) is a prevalent condition in the elderly, presenting unique challenges in diagnosis and treatment due to its varied presentation and the overall medical condition of the patients.</p>
<p>In this DermTalks podcast episode, Dr. Stine Simonsen, clinical associate professor at the university of Copenhagen and dermatologist at the Copenhagen University Hospitals in Denmark, shares her insights on managing atopic dermatitis in the elderly population.</p>

<p><em>"Atopic dermatitis is prevalent in the elderly and may present in this age group. Special considerations are necessary when treating elderly patients such as considering the patient's overall health, current medications and comorbidities are essential for effective management."</em></p>
<p><strong>Dr. Stine Simonsen<br>
   Dermatologist, Copenhagen University Hospitals, Denmark</strong></p>

<h2>Key highlights</h2>
<p>The elderly population is defined by the OECD as individuals aged 65 years and over, while the United Nations defines an older person as someone over 60 years of age. Atopic dermatitis in the elderly presents unique challenges in diagnosis due to its varied presentation. Also, when considering treatment in this population, it’s essential to account for the patient’s overall medical condition, current medications, and their general physical and mental health status.</p>
<h4>Article of interest:</h4>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/32086792/" target="_blank"><em>Tanei R. Atopic Dermatitis in Older Adults: A Review of Treatment Options. Drugs Aging. 2020 Mar;37(3):149-160</em></a></p>

<h3>Prevalence of AD in the Elderly</h3>
<p>AD is prevalent in the elderly, with onset and clinical course varying<sup>1</sup>. It may present as a new disease in older adults (senile onset), as a recurrence of childhood AD (outgrowth-recurrence form), or as a continuation and/or recurrence of adolescent/adult AD<sup>2</sup>. The prevalence in the elderly varies from 1.2% to 17.1% in studies, with a recent UK study showing a prevalence of 8.2% in adults aged 75-99 years<sup>1</sup>.</p>
<h3>Incidence and Ethnic Differences</h3>
<p>The incidence of AD in the elderly is 8 in 1000 person-years for individuals over 80 years, compared to 174 in 1000 person-years in children under 1 year in the UK. Senile onset AD is higher in males and in Black and Asian populations compared to White ethnic groups and is associated with lower socioeconomic status<sup>1</sup>.</p>
<h3>Clinical Presentation in the Elderly</h3>
<p>AD in the elderly does not have a single presentation<sup>1</sup>. It often manifests as chronic lichenified eczema on the upper body, similar to that seen in adolescents and young adults<sup>2</sup>. The "reverse sign," where the typical distribution of eczema is reversed, is more common in the elderly. AD in the elderly is less likely to affect the face and scalp and more likely to affect the buttocks or genitals. Refractory facial erythema, loss of the lateral eyebrows (Hertoghe sign), Dennie–Morgan infraorbital folds, and neck dermatitis are also observed<sup>2</sup>.</p>
<h3>Diagnostic Challenges</h3>
<p>Diagnosing AD in the elderly can be challenging due to the lack of clear diagnostic criteria. Traditional criteria, such as the UK Working Party or Hanifin and Raika, should be used<sup>2</sup>. When diagnosing AD in the elderly, it is essential to exclude other pruritic skin disorders, such as cutaneous T-cell lymphoma, asteatotic dermatitis, nummular eczema, contact dermatitis, chronic prurigo, adverse drug reactions, scabies, Ofuji disease (in Japanese), chronic eczematous eruption of aging, and eczematous variants of bullous pemphigoid<sup>2</sup>. Extra attention to treatment of refractory disease is needed, and cutaneous T cell lymphoma must be ruled out by histopathology, since this diagnosis should be excluded before initiating any systemic therapy<sup>2,4</sup>.</p>
<h3>Immune Mechanisms</h3>
<p>Adult-onset AD patients may be less likely to have IgE-specific allergies and filaggrin mutations compared to childhood-onset AD<sup>1</sup>. In elderly patients with high serum total IgE, Th2 cytokines (IL-4, IL-5, and IL-13) dominate in peripheral blood, while Th1 cytokines (IFN-γ) dominate in those with low serum total IgE. In the skin, elderly patients with AD show decreased Th2 and Th22 cytokines and increased Th1 cytokines in lesional skin compared to adult AD patients<sup>2</sup>.</p>
<h3>Considerations for Treatment</h3>
<p>When choosing therapies for elderly patients, considerations include cognitive ability, functional independence, ability to self-administer medication, renal function, comorbidities, polypharmacy, and drug interactions<sup>2-4</sup>. Data supporting treatment choices for elderly patients with AD are limited due to their exclusion from trials (upper age limit or comorbidities). A systematic review of randomized controlled trials (RCTs) from 2020 of systemic immunomodulatory treatments for AD, found that in the trials reporting proportion of participants aged 65 or older, 4% were 65 or older<sup>5</sup>.</p>
<p>Comorbidities such as heart disease, cerebrovascular disease, diabetes mellitus, chronic renal disease, and osteoporosis and pharmacological interactions must be considered when starting systemic treatment<sup>3</sup>.</p>
<h4>1. Topical therapies</h4>
<p>Basic treatment is similar to other age groups, however, applying sufficient topical medication may be difficult or even become a burden. Therefore, solutions to this challenge should be considered, including help from relatives or community-based caregivers<sup>2</sup>.</p>
<h4>2. Phototherapy</h4>
<p>Phototherapy may be burdensome or even impossible for some elderly patients due to the number of visits needed per week<sup>2,3</sup>.</p>
<h4>3. Systemic Therapies</h4>
<p>Traditional systemic therapies are effective in the elderly, but due to comorbidities, the risk of skin cancer, and the risk of infection, cyclosporine, azathioprine, and mycophenolate mofetil are not the best choices. Methotrexate may be considered, but it is advised to use a lower starting dose<sup>2-4,14-17</sup>.</p>
<h4>4. Biologics</h4>
<p>Biologics such as dupilumab and tralokinumab are reasonable treatment options, with data showing similar efficacy in the elderly as in other age groups<sup>6,8</sup>. These treatments are well tolerated, no routine screening and monitoring are required, and no interactions are known<sup>9,10</sup>.</p>
<h4>5. Janus Kinase Inhibitors</h4>
<p>JAK inhibitors are indicated for elderly patients with AD, but caution is needed in patients over 65 years of age due to the higher risk of serious infections, cardiovascular disease, malignancies, thromboembolic events, and mortality. For those patients, a lower starting dose is indicated, and careful monitoring is recommended, alongside with screening for risk factors such as increased cardiovascular events, increased risk of cancer, and smoking<sup>11-13</sup>.</p>
<h3>Conclusion</h3>

<p>Atopic dermatitis is prevalent in the elderly and may present in this age group. Like pediatric AD or adult AD, it is driven by a Th2 pathway. Special considerations are necessary when treating elderly patients such as considering the patient's overall health and comorbidities are essential for effective management.</p>

ATOPIC-DERMATITIS

DERMATOLOGY

<p>CLICK HERE TO READ DUPIXENT COMPULSORY INFORMATION</p>

Speaker : Dr. Stine Simonsen, Copenhagen University Hospitals, Denmark

Managing Atopic Dermatitis in the Elderly

<p>Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition that affects more than 20% of children in industrialized countries<sup>1</sup>. Children who develop AD have a higher risk of developing other allergic diseases such as allergic asthma, allergic rhinitis, and food allergies<sup>2</sup>. This is why, in the management of pediatric AD, the atopic march and possible food allergies needs to be carefully considered.</p>
<p>In this DermTalks podcast episode, Dr. Hannah de Leye, physician, and dermatologist in training at UZ Brussel, currently working at UZ Leuven in Belgium, shares her insights on the atopic march, food allergies, including IgE testing and restrictive diets, as well as early interventions that may help restore skin barrier function and prevent the progression of atopic diseases.</p>

<p><em>"As AD often precedes the development of other atopic diseases, early intervention in young pediatric patients could possibly restore epithelial barrier integrity and function, potentially preventing the inflammatory response and the development of the atopic march<sup>2,12</sup>.</em></p>
<p><em>Consulting with a pediatrician and food allergy specialist before starting a restrictive diet in any child with AD is essential. Specific IgE testing is often used in clinical practice as a work-up in children with AD, but these tests often have no value in diagnosing real food allergy and can lead to unnecessary elimination of foods. It is important to ask about other symptoms and consider the child's overall health and growth<sup>7-10</sup>."</em></p>
<p><strong>Dr. Hannah de Leye<br>
   Dermatologist in training, UZ Brussel, Belgium</strong></p>

<h2>Key highlights</h2>
<p>The prevalence of atopic comorbidities in AD at any age is higher than in the general population, with AD and these comorbidities exhibiting numerous shared genetic risk variants<sup>5</sup>. More severe AD is associated with an increased likelihood of atopic comorbidities, including asthma<sup>2,6</sup>.</p>
<h4>Article of interest:</h4>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/34943362/" target="_blank"><em>Ghezzi M et al. Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective. Children (Basel). 2021 Dec 9;8(12):1165.</em></a></p>

<h3>The Atopic March</h3>
<p>The concept of the "atopic march" describes the sequential progression of AD, food allergy (FA), allergic asthma (AA), allergic rhinitis (AR), and allergic conjunctivitis (AC)<sup>2</sup>. According to this theory, the disruption of the epidermal barrier in AD triggers sensitization to epicutaneous allergens and inflammation, leading to an immune response that subsequently extends to other epithelial surfaces, including the gastrointestinal tract, resulting in food allergies, the upper respiratory tract, leading to allergic rhinitis, and the lower respiratory tract, contributing to allergic asthma<sup>2,3</sup>.</p>
<h3>Food Allergy in Young Children with AD</h3>
<p>Infants with AD have a six-fold higher risk of developing IgE-mediated food allergy compared with infants without AD<sup>7</sup>. Symptoms often include gastrointestinal issues such as vomiting, diarrhea, constipation, cramps, and lung manifestations.</p>
<h3>Management of Food Allergy: Do’s and Don’t</h3>
<p>Dermatologists and general practitioners frequently search for links between skin exacerbations and food, leading to prescribed skin prick tests and specific IgE tests in blood. However, sensitization to many food elements is often found in children with AD, resulting in prescribed diets<sup>7</sup>.</p>
<h4>1. Restrictive diets</h4>
<p>Recent studies have shown the importance of including common food allergens in the diets of infants<sup>9</sup>. Dietary elimination for the treatment of AD may slightly improve the condition but does not account for the potential harm of a diet in young children. Some studies suggest that diet restriction at a young age can increase the risk of developing food allergies, as exposure to different types of food is necessary to maintain immune tolerance. Elimination of certain foods may improve AD in some patients with true food-triggered AD but can also lead to the future development of IgE-mediated FA, including anaphylaxis. Furthermore, children who eliminate two or more foods from their diet are more likely to reach lower height percentiles and be vitamin D deficient. Therefore, a general diet based on specific IgE tests should be approached with caution<sup>7,8</sup>.</p>
<h4>2. IgE testing</h4>
<p>Specific IgE testing may be useful in predicting food allergy in patients with moderate-severe AD, but the decision points may be much higher than those that apply to a less atopic population<sup>8</sup>. Furthermore, IgE testing alone is not diagnostic for food allergies, so adding a diagnostic oral food challenge could help guide the clinical significance of specific IgE sensitization<sup>10</sup>.</p>
<h3>The Benefits of Early intervention in Children</h3>
<p>An intact skin epithelium is crucial for preventing further allergic manifestations. There is some evidence, although not established, that early application of skin emollients can reduce the risk of AD development or delay its onset<sup>11</sup>. This also raises the question of whether treatment with biologics that restore epithelial barrier integrity may prevent the inflammatory response and the development of the atopic march<sup>12</sup>. Since treatment with biologics is now approved at a very young age, future research will be able to answer this question<sup>12</sup>.</p>
<h3>Conclusion</h3>

<p>As AD often precedes the development of other atopic diseases, early intervention in young pediatric patients could possibly restore epithelial barrier integrity and function, potentially preventing the inflammatory response and the development of the atopic march<sup>2,12</sup>. Consulting with a pediatrician and food allergy specialist before starting a restrictive diet in any child with AD is essential. Specific IgE testing is often used in clinical practice as a work-up in children with AD, but these tests often have no value in diagnosing real food allergy and can lead to unnecessary elimination of foods. It is important to ask about other symptoms and consider the child's overall health and growth<sup>7-10</sup>.</p>

<p data-font="small">CLICK HERE TO READ DUPIXENT COMPULSORY INFORMATION</p>

Speaker : Dr. Hannah de Leye, UZ Brussel, Belgium

Managing Pediatric Atopic Dermatitis

<p>Watch this engaging and educational session tailored for pulmonologists looking to deepen the understanding of Chronic Obstructive Pulmonary Disease (COPD) and the latest advancements in biologic therapies.</p>
<h2>Meet Our Expert Panel</h2>

<ul>
 <li><strong>Prof. Dr. Frits Franssen</strong><br>
   Pulmonologist, Maastricht UMC+, the Netherlands<br>
   &nbsp;</li>
 <li><strong>Dr. Asger Sverrild</strong><br>
   Pulmonologist, Bispebjerg Hospital, Denmark<br>
   &nbsp;</li>
 <li><strong>Prof. Dr. Wim Janssens</strong><br>
   Pulmonologist, UZ Leuven, Belgium<br>
   &nbsp;</li>
 <li><strong>Prof. Dr. Janwillem Kocks</strong><br>
   General Practitioner, GPRI &amp; UMCG, the Netherlands</li>
</ul>

<h2>Watch the Full Webinar</h2>
<p>Don’t miss the opportunity to access the complete webcast <strong>Targeting COPD with type 2 inflammation - emerging biologic landscape</strong>.</p>

Explore the Latest Insights in COPD Management and Biologic Therapies.

CHRONIC-OBSTRUCTIVE-PULMONARY-DISEASE-(COPD)

Webcast: Targeting COPD with type 2 inflammation - emerging biologic landscape

<h2>Webcast segments</h2>
<p>You can also watch specific parts of the webcast in the separate videos provided below.</p>

<h2>Introduction to the webcast: Targeting COPD with type 2 inflammation - emerging biologic landscape</h2>

<p>Presented by <strong>Prof. Dr. Janwillem Kocks</strong>, this session provides an overview of COPD, its prevalence, and its impact on patient health.</p>

<h2>Evolving Clinical Landscape in COPD and Implications for Disease Management</h2>

<p>Gain insights into the latest advancements in COPD treatments and their effect on disease management strategies, presented by&nbsp;<b>Prof. Dr. Wim Janssens</b>.</p>

<h2>Heterogeneity of Inflammation Pathways in COPD</h2>

<p>Understand the diverse inflammation pathways in COPD and their implications for personalized care, presented by<strong> Dr. Asger Sverrild</strong>.</p>

<h2>Clinical Presentation of COPD Through Disease Pathology</h2>

<p>Explore the clinical features and underlying mechanisms of COPD with this video presented by <b>Prof. Dr. Frits Franssen</b>.</p>

<p>Are you interested in learning more about managing atopic dermatitis in specific patient groups? Look no further and listen to the DermTalks Podcast - Atopic Dermatitis in Special Populations!</p>
<p>Over the course of four episodes, dermatologists from North-European countries will focus on one specific group of patients.</p>

DermTalks Podcasts – Atopic Dermatitis in Special Populations

Voor uw intercontext, meld u aan bij uw account Sanofi Campus. Geef uw e-mail door aan uw e-mail.

Als u onze eerste e-mail op <strong>{email}</strong> tot bevestig uw account u kunt hieronder een nieuwe aanvragen. Als je het niet ziet, moet je mogelijk <strong>je spammap</strong> controleren.

Deze informatie wordt alleen gebruikt om uw account te valideren en wordt niet verspreid.

titel

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

Om u een gepersonaliseerde ervaring te bieden, moet u

Je profiel is onvolledig

De ADCT geeft een indicatie van hoe gecontroleerd het eczeem is. Beantwoord deze 6 eenvoudige vragen met uw patiënt om de ADCT-score te vinden. Het zal de juiste handelwijze aangeven.

Atopische dermatitis, een vorm van eczeem, kan het leven van uw patiënt op meer manieren beïnvloeden dan u weet.

Doe de atopische dermatitis controle test (ADCT)

Geniet van meer exclusieve inhoud{newline}door <a>door u vandaag te registreren</a>

Heb je al een account? <a>Hier inloggen</a>

Best practices voor het optimaliseren van de patiëntenzorg

Krijg een aangepast beeld van de onderwerpen waarin u geïnteresseerd bent, samen met de mogelijkheid om inhoud op te slaan om op een later tijdstip te bekijken of te lezen.

Onbeperkte toegang tot eersteklas inhoud, whitepapers, casestudy's, onderzoekspapers, webinars, training en up-to-date wetenschappelijke medische bronnen.

Gepersonaliseerde inhoud op basis van uw interessegebieden

Maak contact en blijf up-to-date met collega's op uw vakgebied en onderwerpen die u interesseren via gratis evenementen en leidinggevende forums.

Registreer om het volledige artikel te lezen.

Wij respecteren uw privacy en zullen uw informatie niet delen met derden.

Actuele gidsen die speciaal voor patiënten zijn geschreven

Onbeperkte toegang tot de nieuwste patiëntengidsen en bronnen. Deel inhoud met uw patiënten met gebruiksvriendelijke online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Beperkte toegang

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

Normaal gesproken bieden we een schat aan kenis, maar we konden niet vinden waar je naar op zoek bent.

We konden niet vinden wat je zocht

Sanofi is niet verantwoordelijk voor de inhoud van deze externe website.

U staat op het punt Campus.sanofi/nl te verlaten.

Images from <a>iStockphoto.com</a>, <b>Fotolia.de</b>, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Volg ons:

<strong>Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.</strong><br></br><br></br><br></br>

<strong>Please follow these steps to complete your registration:</strong><br></br><br></br>

<strong>Would you like to receive future text messages about Beyfortus updates?</strong>

<strong>Sanofi is here to help support your patients, their families, and caregivers.</strong><br></br><br></br>For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text.<br></br><br></br><strong>All fields are required.</strong>

Would you like to learn more about Beyfortus<sup>®</sup> (nirsevimab-alip) 50 mg and 100 mg injection?<br></br>Leave us your contact details, and a Sanofi representative will be in touch.<br></br><br></br><strong>All fields are required.</strong>

<strong>Would you also like to receive future messages and updates about Beyfortus?</strong>

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Request a visit from your local ALTUVIIIO representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Request a visit from your local QFITLIA representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX.<br></br><br></br>Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia.<br></br><br></br>Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required (unless otherwise specified).</strong>

Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een lijst met evenementen en tools en diensten voor uw dagelijkse praktijk.

Bevestig uw status

De inhoud van deze website is alleen toegankelijk voor geregistreerde gebruikers.

Log in alstublieft

Email verificatie

U ziet een voorbeeld van de portal. Wis uw cookies (bijvoorbeeld door uw browservenster te sluiten) om terug te gaan naar de openbare modus.

We hebben onze privacyverklaring bijgewerkt om je gegevens beter te beschermen en je ervaring te verbeteren. Neem even de tijd om de wijzigingen door te nemen door <privacyNewTab>hier te klikken</privacyNewTab>. Uw privacy is belangrijk voor ons. <br></br>Klik op doorgaan om te bevestigen dat u de nieuwe privacyverklaring hebt gelezen.

Update van de privacyverklaring

Communicatie toestemming

My consents

Password

Confirm password

{resultsCount, plural, one {resultaat} other {resultaten}}

Log in om toegang te krijgen tot de resultaten

U moet inloggen op uw account om toegang te krijgen tot medische inhoud.

Inloggen

Registreer in minder dan 1 minuut om toegang te krijgen tot de resultaten

U verlaat nu het Sanofi inhoudsgedeelte van onze site en komt in het inhoudsgedeelte voor extern medisch bibliografisch zoeken.

U verlaat nu het externe medische bibliografische zoekgedeelte van onze site en komt in het inhoudsgedeelte van Sanofi.

Educatie